- Home
- APM vs BTAI Comparison
APM vs BTAI Comparison
Compare APM & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- BTAI
- Stock Information
- Founded
- APM 2010
- BTAI 2017
- Country
- APM United Kingdom
- BTAI United States
- Employees
- APM N/A
- BTAI N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- BTAI Health Care
- Exchange
- APM Nasdaq
- BTAI Nasdaq
- Market Cap
- APM 6.7M
- BTAI 7.2M
- IPO Year
- APM 2018
- BTAI 2018
- Fundamental
- Price
- APM $0.88
- BTAI $1.99
- Analyst Decision
- APM
- BTAI Buy
- Analyst Count
- APM 0
- BTAI 5
- Target Price
- APM N/A
- BTAI $42.60
- AVG Volume (30 Days)
- APM 27.5K
- BTAI 1.2M
- Earning Date
- APM 04-29-2025
- BTAI 03-27-2025
- Dividend Yield
- APM N/A
- BTAI N/A
- EPS Growth
- APM N/A
- BTAI N/A
- EPS
- APM 0.00
- BTAI N/A
- Revenue
- APM N/A
- BTAI $2,266,000.00
- Revenue This Year
- APM $157,729.10
- BTAI $105.36
- Revenue Next Year
- APM N/A
- BTAI $46.93
- P/E Ratio
- APM $242.56
- BTAI N/A
- Revenue Growth
- APM N/A
- BTAI 64.20
- 52 Week Low
- APM $0.46
- BTAI $1.72
- 52 Week High
- APM $11.19
- BTAI $49.58
- Technical
- Relative Strength Index (RSI)
- APM 42.47
- BTAI 39.93
- Support Level
- APM $0.85
- BTAI $1.76
- Resistance Level
- APM $1.00
- BTAI $2.11
- Average True Range (ATR)
- APM 0.07
- BTAI 0.28
- MACD
- APM 0.00
- BTAI 0.02
- Stochastic Oscillator
- APM 39.15
- BTAI 16.98
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.